Skip to main content

Table 7 Trials comparing HSCT with haploidentical donor and matched sibling donor

From: The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update

References

Diagnosis

aGVHD II-IV

cGvHD

CIR

LFS or GRFS

OS

Chang et al. [88]

Adult FCM MRD + AML

HID vs. MSD

HID: 28–36%

MSD: 5–7%

HID: 70–73%

MSD: 41–66%

19 vs. 55%, p < 0.001

74 vs. 33%, p < 0.001

83 vs. 38%, p = 0.001

Yu et al. [91]

Adult High-risk

AML CR1 HID vs. MSD

HID: 40%

MSD: 46%

HID: 39%

MSD: 51%

14 vs. 24%, p = 0.101

LFS 71 vs. 66%, p = 0.579

GRFS 64 vs. 43%; p = 0.035

72 vs. 68%, p = 0.687

Zheng et al. [92]

Children High-risk

AML CR1 HID vs. MSD

HID: 35%

MSD: 13%

HID: 35%

MSD: 14%

50.0 vs. 9.2%, p = 0.001

81.2 vs. 50.0%, p = 0.021

81.5 vs. 68.8%; p = 0.196

Guo et al. [103]

MRD + AML-ETO

HID vs. MSD

Not report

Not report

14 vs. 25%; p = 0.036

68 vs. 48%;p = 0.026

70 vs. 50%; p = 0.062

Chang et al. [89]

Adult FCM MRD + ALL

HID vs. MSD

HID: 21%

MSD:23%

HID: 41%

MSD: 48%

23 vs. 47%, p = 0.006

65 vs. 43%, p = 0.023

68 vs. 46%, p = 0.039

Li et al. [90]

Adult MRD + Ph + ALL

HID vs. MSD

HID: 22.0%

MSD:23.8%

HID: 38.5%

MSD: 38.3%

14.8 vs. 56.4%, p = 0.021

77.7 vs. 35.9%, p = 0.036

80.5 vs. 35.9%, p = 0.027

Gao et al. [26]

Adult and children

Ph + ALL HID vs. MSD

HID:51.1%

MSD:25.7%

HID:48.9%

MSD:25.7%

19.1 vs 44.8%, p = 0.036

59.5 vs 45.7%, p = 0.118

63.8 vs 62.6%, p = 0.743

Wang et al. [102]

Elderly AL HID with young donor vs. MSD

HID: 35%

MSD:26%

HID: 24%

MSD: 37%

6 vs. 17%; p = 0.066

85 vs. 56%; p = 0.001

85 vs. 58%; p = 0.003

  1. AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; aGVHD, acute graft-versus-host-disease; CT, Chemotherapy; cGVHD, chronic graft-versus-host-disease;
  2. FCM, multiparameter flow cytometry; HSCT, hematopoietic stem cell transplantation; HID, haploidentical donor; LFS, leukemia-free survival; MSD, matched sibling donor; MRD, minimal (or measurable) residual disease